Genelux Q3 Loss Widens to $10.3M; Going Concern Reaffirmed, Runway Into Q1 2027
GNLX is trading near its 52-week low of $1.77 (6.2% above the low).
Summary
Genelux's Q3 loss widened to $10.3 million on higher Phase 3 costs, and with $15.5 million pro forma liquidity the going concern warning stands with runway only into Q1 2027.
Key Events · Earnings and Guidance · GNLX
-
Q3 Loss Widens on Phase 3 Costs
Net loss was $10.285 million ($0.23 per share) versus $7.950 million a year earlier, above the $8.78 million consensus; R&D rose to $6.909 million from $4.741 million on the Phase 3 On Prime/GOG-3076 trial.
-
Going Concern and Q1 2027 Runway
The company reaffirmed substantial doubt about its ability to continue as a going concern, with $10.4 million of cash, equivalents, restricted cash and marketable securities at September 30, 2026 expected to fund operations only into the first quarter of 2027.
-
ATM Sales Fund the Gap
135,000 shares were sold for $0.4 million net in Q3, and 2,552,458 shares for $5.1 million net in October-November 2026, bringing pro forma liquidity to $15.5 million.
-
Cash Burn of $18.4 Million
Operating activities used $18.429 million in the first nine months of 2026, against a $28.685 million net loss, with stock-based compensation of $6.990 million as the main non-cash add-back.
Analysis · GNLX · Life Sciences
The going concern warning is not boilerplate: Genelux burned $18.4 million of cash in the first nine months of 2026 and ended September with $10.4 million of cash and securities, leaving roughly one quarter of funding without new capital. The Q3 loss of $10.3 million ($0.23 per share) came in above the $8.78 million consensus as Phase 3 On Prime/GOG-3076 trial costs pushed R&D to $6.9 million from $4.7 million a year ago. Management has been plugging the gap with the TD Securities ATM: 135,000 shares for $0.4 million in Q3 and another 2,552,458 shares for $5.1 million net in October-November, lifting pro forma liquidity to $15.5 million. That buys time into Q1 2027 but not through the trial, so another raise — and more dilution — is the base case.
How filings like this one have moved
In the 30 days to Nov 15, 2026, 48.2% of the 1980 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.20%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, GNLX was trading at $1.88 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $86.9M. The 52-week trading range was $1.77 to $5.89. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.